This medicine is now known as avacopan.

On 19 November 2014, orphan designation (EU/3/14/1372) was granted by the European Commission to ChemoCentryx Limited, United Kingdom, for (2R,3S)-2-(4-cyclopentylaminophenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid(4-methyl-3-trifluoromethylphenyl)amide for the treatment of microscopic polyangiitis.

The sponsorship was transferred to Chemocentryx Ireland Limited, Ireland, in February 2019.

Key facts

Active substance
(2R,3S)-2-(4-cyclopentylaminophenyl)-1-(2-fluoro-6-methylbenzoyl)piperidine-3-carboxylic acid(4-methyl-3-trifluoromethylphenyl)amNide
Disease / condition
Treatment of microscopic polyangiitis (avacopan)
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Chemocentryx Ireland Limited
70 Sir John Rogerson's Quay
Dublin 2
Co. Dublin
Tel: +353 1 232 2000


Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating